The publication is reproduced in full below:
{time} 1630
SUPPORTING THE FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH AND THE
REAGAN-UDALL FOUNDATION FOR THE FOOD AND DRUG ADMINISTRATION ACT
Mr. PALLONE. Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 3743) to increase funding for the Reagan-Udall Foundation for the Food and Drug Administration and for the Foundation for the National Institutes of Health.
The Clerk read the title of the bill.
The text of the bill is as follows:
H.R. 3743
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act''.
SEC. 2. REAGAN-UDALL FOUNDATION AND FOUNDATION FOR THE
NATIONAL INSTITUTES OF HEALTH.
(a) Reagan-Udall Foundation for the Food and Drug Administration.--Section 770(n) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379dd(n)) is amended by striking
``$500,000 and not more than $1,250,000'' and inserting
``$1,250,000 and not more than $5,000,000''.
(b) Foundation for the National Institutes of Health.--Section 499(l) of the Public Health Service Act (42 U.S.C. 290b(l)) is amended by striking ``$500,000 and not more than
$1,250,000'' and inserting ``$1,250,000 and not more than
$5,000,000''.
The SPEAKER pro tempore. Pursuant to the rule, the gentleman from New Jersey (Mr. Pallone) and the gentleman from Kentucky (Mr. Guthrie) each will control 20 minutes.
The Chair recognizes the gentleman from New Jersey.
General Leave
Mr. PALLONE. Mr. Speaker, I ask unanimous consent that all Members may have 5 legislative days in which to revise and extend their remarks and include extraneous material on H.R. 3743.
The SPEAKER pro tempore. Is there objection to the request of the gentleman from New Jersey?
There was no objection.
Mr. PALLONE. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I rise today in support of H.R. 3743, the Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act.
The Reagan-Udall Foundation for the FDA is an independent nonprofit organization established by Congress in 2007 to advance the mission of the FDA to modernize medical product development, accelerate innovation, and enhance safety.
Likewise, the Foundation for the NIH is an independent nonprofit organization established by Congress in 1990 to develop private-public partnerships that advance biomedical research, domestically and globally.
Both organizations work to advance the missions of the NIH and the FDA and have played important roles in our Nation's fight against COVID-19. For example, the Foundation for the NIH has worked to coordinate the ACTIV program that is strategizing our research and prioritizing and speeding development of the most promising COVID-19 vaccines and treatment. Likewise, the Reagan-Udall Foundation's COVID-
19 Diagnostics Evidence Accelerator has brought stakeholders together to collect and evaluate real-world data in a way that is scientifically useful and meets the FDA standards so we can understand the efficacy of COVID-19 diagnostics in the real world.
Mr. Speaker, the FDA and the NIH are currently authorized to transfer funding to their respective foundations within a statutory limit that has not been increased since 2007.
H.R. 3743 would increase the transfer authority for both foundations from up to $1.25 million to up to $5 million. This legislation will allow the agencies to increase their support consistent with the increasing costs of medical product research and development.
This bipartisan bill received unanimous support in the Energy and Commerce Committee. I would like to thank my colleagues, Representative Hudson and Health Subcommittee Chairwoman Eshoo, for their outstanding leadership on this legislation.
Mr. Speaker, I urge my colleagues to support H.R. 3743, and I reserve the balance of my time.
Mr. GUTHRIE. Mr. Speaker, I yield myself such time as I may consume.
Mr. Speaker, I rise today in support of H.R. 3743, Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act, led by my Energy and Commerce Committee colleagues, Representative Hudson and Representative Eshoo.
Empowering biomedical innovation in the United States is critical to protecting our global competitiveness. We saw how important it was to invest in creating new treatments during the COVID-19 pandemic, and we need to carry that momentum into the future.
H.R. 3743 authorizes increased transfer authorities from the FDA and the NIH to both the Reagan-Udall Foundation and the Foundation for the NIH, respectively.
Allowing FDA and NIH to provide increased funding to these public-
private partnerships will give the Reagan-Udall Foundation and the Foundation for the NIH more flexibility to meet the growing research demands and to ultimately accelerate future medical innovations.
I urge my colleagues to support this bill, and I reserve the balance of my time.
Mr. PALLONE. Mr. Speaker, I have no Members who wish to speak at this time, and I reserve the balance of my time.
Mr. GUTHRIE. Mr. Speaker, I yield as much time as he may consume to the gentleman from North Carolina (Mr. Hudson).
Mr. HUDSON. Mr. Speaker, I rise in support of H.R. 3743, Supporting the Foundation for the NIH and the Reagan-Udall Foundation for the FDA Act.
I introduced this bipartisan bill along with my friend, Chairwoman Anna Eshoo, to build on our success of public-private partnerships that have produced lifesaving medical breakthroughs.
The Foundation for the NIH and the Reagan-Udall Foundation were created by Congress to support the NIH and the FDA by forging partnerships between the Federal Government and private industry experts.
Providing additional support to these organizations would further accelerate research into novel vaccines, therapeutics, diagnostics, and other innovations, helping us prepare for future emergencies.
Due to partnerships such as these, we have already seen the success of the ACTIV program in speeding developments of COVID-19 vaccines and treatments.
It should be noted that we would not be where we are today without the innovation seen in Operation Warp Speed. This public-private partnership has not received the credit it deserves for creating, developing, and manufacturing life-saving vaccines in record time.
Through my legislation, we can build on these successes and enhance partnerships across the healthcare industry.
I thank Chairman Pallone and Ranking Member Guthrie for their support, and I urge my colleagues to support this legislation.
Mr. GUTHRIE. Mr. Speaker, I yield back the balance of my time.
Mr. PALLONE. Mr. Speaker, I urge support for this bill, and I yield back the balance of my time.
The SPEAKER pro tempore. The question is on the motion offered by the gentleman from New Jersey (Mr. Pallone) that the House suspend the rules and pass the bill, H.R. 3743.
The question was taken.
The SPEAKER pro tempore. In the opinion of the Chair, two-thirds being in the affirmative, the ayes have it.
Mrs. BOEBERT. Mr. Speaker, on that I demand the yeas and nays.
The SPEAKER pro tempore. Pursuant to section 3(s) of House Resolution 8, the yeas and nays are ordered.
Pursuant to clause 8 of rule XX, further proceedings on this motion are postponed.
____________________
SOURCE: Congressional Record Vol. 167, No. 206
The Congressional Record is a unique source of public documentation. It started in 1873, documenting nearly all the major and minor policies being discussed and debated.
House Representatives' salaries are historically higher than the median US income.
Alerts Sign-up